华海药业：关于子公司药物临床试验进展的公告

Core Points - Huahai Pharmaceutical announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., and its wholly-owned subsidiary, Huabo Biopharmaceutical Technology (Shanghai) Co., Ltd., have successfully completed a key clinical trial for HB0017 injection for the treatment of psoriasis, achieving all primary and key secondary efficacy endpoints [2] Group 1 - The clinical trial was a multicenter, double-blind, randomized, placebo-controlled study [2] - The trial results indicate significant efficacy of HB0017 in treating psoriasis [2] - This development may enhance Huahai Pharmaceutical's position in the biopharmaceutical market [2]